Penumbra
PENPenumbra is a global healthcare company specializing in the development and commercialization of innovative medical devices for challenging vascular conditions.
Earnings
Next report
Aug 4, 2026 (In 3 weeks)Valuation & ratios
Segments
By product
Competitors
By market cap
By revenue growth
Profile
Penumbra is a global healthcare company specializing in the development and commercialization of innovative medical devices for challenging vascular conditions. The company's core value proposition centers on its computer-assisted vacuum thrombectomy (CAVT) technology, designed to remove blood clots with speed and safety across various anatomical locations. Its portfolio addresses critical needs in ischemic stroke, pulmonary embolism, and acute limb ischemia for specialist physicians.
Penumbra is a global leader in the thrombectomy market, characterized by rapid product iteration and a transition toward computer-assisted mechanical intervention.
Questions, answered.
- What is Penumbra's market cap?
- Penumbra (PEN) has a market capitalization of $12.5B and trades on NYSE.
- What is Penumbra's revenue and profitability?
- Penumbra generated $1.5B in trailing twelve-month revenue with net income of $171.0M, representing a net margin of 11.8%. Gross margin stands at 67.4%, with free cash flow of $212.7M. These figures are based on the Q1 2026 filing.
- Who are Penumbra's competitors?
- Penumbra's key competitors include Medtronic plc, Stryker Corporation, Johnson & Johnson, and others. These companies compete in similar markets and product categories.
- Who does Penumbra partner with?
- Penumbra's notable partners include Boston Scientific Corporation.
- What subsidiaries does Penumbra have?
- Penumbra's subsidiaries include Pinehurst Merger Sub, Inc..
- Where is Penumbra headquartered?
- Penumbra is headquartered in United States of America and employs approximately 4,200 people. It has been publicly traded since 2015.
